Loading market dashboard
West Pharmaceutical Services, Inc.
WSTHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
The Microsoft founder's foundation recently added this healthcare stock to its portfolio.
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026.
On May 21, 2026, West Pharmaceutical Services Inc (WST) shares rose 3.5% to $316.13. This uptick comes amidst a positive price performance, with shares having t
West Pharmaceutical Services, Inc. WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
West Pharmaceutical Services said on Wednesday it has restored operations across its sites after a cybersecurity attack earlier this month and expects the incident to have no material impact on its 2026 financial outlook.
West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript
West Pharmaceutical Services Inc. (NYSE:WST) on Monday disclosed a material cybersecurity attack on May 7, saying an unauthorized party exfiltrated data and encrypted certain systems.
Investors interested in Medical - Dental Supplies stocks are likely familiar with Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now?
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
From a technical perspective, West Pharmaceutical Services, Inc. (WST) is looking like an interesting pick, as it just reached a key level of support. WST's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength.
Comerica Bank boosted its holdings in West Pharmaceutical Services, Inc. (NYSE: WST) by 31.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 56,693 shares of the medical instruments supplier's stock after acquiring an additional 13,680 shares during the period.
Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FIX, DVN and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 29th, 2026.
West Pharmaceutical Services (NYSE: WST | WST Price Prediction) has ripped 24.2% in the past month and 8.7% in the past week, and the move has the fingerprints of a sustained re-rating.
EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Bank of America Global Healthcare Conference on Tuesday, May 12, 2026 at 2:20 p.m. PDT in Las Vegas, NV William Blair Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:00 p.m.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Shares of West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report) have received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a
HB Wealth Management LLC decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 27.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,850 shares of the medical instruments supplier's stock after selling 3,325 shares during the
West Pharmaceutical Services delivered a beat-and-raise 1Q26, with adjusted EPS of $2.13 and revenue of $844.9M, both well ahead of expectations. WST's growth is driven by robust demand for High-Value Product components, biologics, and a favorable mix shift, supporting margin expansion and durable earnings momentum. Management raised FY26 guidance to $3.35B revenue and $8.75 adjusted EPS, reflecting operational strength but maintaining a conservative outlook amid macro uncertainties.
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the company's first-quarter 2026 earnings surpassed analyst estimates.
West Pharmaceutical posts 46.9% EPS growth and beats estimates as strong segment demand lifts revenues, prompting a higher 2026 outlook and margin expansion.
West Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Call Transcript
The headline numbers for West Pharmaceutical (WST) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.45 per share a year ago.
On April 23, 2026, West Pharmaceutical Services Inc (WST) released its 8-K filing reporting first-quarter 2026 results. The company posted net sales of $844.9 m
West Pharmaceutical on Thursday raised its annual profit and revenue forecasts after beating estimates for first-quarter results, betting on strong demand for its proprietary products that include syringes and cartridges for injectable drugs.
Strong Start to the Year and Raising Full-Year Revenue and EPS guidance EXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026.
WST enters Q1 earnings with strong momentum, steady GLP-1 demand, and growth across high-value products, positioning it for another potential beat.
Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
WST rides strong HVP demand and GLP-1 expansion, but tariffs, destocking pressures and European facility constraints pose near-term growth risks.
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Align Technology (ALGN) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
West Pharmaceutical expands Dublin facility to boost injectable therapy capacity and strengthen its end-to-end manufacturing platform.
I am shifting capital allocation toward scarcity-driven assets like energy, metals, infrastructure, and defense, as the abundance trade in software faces structural disruption from AI. My TOLL framework prioritizes companies with hard assets, durable competitive moats, and long-duration cash flows that are less vulnerable to AI-driven commoditization. Key investment themes include nuclear utilities (VST, CEG), copper producers (FCX), gold/silver streamers (FNV, WPM), grid/infrastructure suppliers (ETN, FIX), and defense/aerospace leaders (RTX, TDG).
EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity.
Wealth Enhancement Advisory Services LLC trimmed its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 26.4% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,480 shares of the medical instruments supplier's stock after selling 7,693 shares during the period. Wealth Enhancement
Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
West Pharmaceutical Services, Inc. (WST) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 14,319 shares of the medical instruments supplier's stock, valued at approximately $3,756,000. Other institutional
Brown Brothers Harriman and Co. lifted its holdings in West Pharmaceutical Services, Inc. (NYSE: WST) by 22.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 247,356 shares of the medical instruments supplier's stock after purchasing an
Middle East tensions rattle markets as oil tops $100. Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services stand out as dividend aristocrats for stability.
WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.
West Pharmaceutical Services, Inc. (WST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
West Pharmaceutical's chief executive Eric Green said on Monaday he plans to retire once the company finds his successor, ending an 11-year run at the helm.
EXTON, Pa., March 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition.
Blair William and Co. IL decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 10.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,999 shares of the medical instruments supplier's stock after selling 7,737 shares during
Fisher Asset Management LLC lessened its holdings in West Pharmaceutical Services, Inc. (NYSE: WST) by 9.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,949 shares of the medical instruments supplier's stock after selling 2,389 shares during the quarter. Fisher
